The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).

被引：1
|
作者：
Hadji, P.
Ziller, M.
Maurer, T.
Muth, M.
Ruebel, A.
May, C.
Birkholz, K.
Gschwend, J. E.
机构：
[1] Univ Marburg, Marburg, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, D-80290 Munich, Germany
[3] Novartis Pharma GmbH, Nurnberg, Germany
[4] Novartis GmbH, Nurnberg, Germany
[5] Novartis Pharmaceut, Nurnberg, Germany
[6] Tech Univ Munich, D-80290 Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4614
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4614
引用
收藏
页数：1
相关论文
共 50 条
  • [1] THE ZOTECT STUDY: EFFECT OF INTRAVENOUS ZOLEDRONIC ACID ON BONE METABOLISM IN PATIENTS WITH METASTATIC BONE DISEASE IN BREAST CANCER AND PROSTATE CANCER
    Gschwend, J.
    Ziller, M.
    Kalder, M.
    Muth, M.
    Ruebel, A.
    Schmidt, K.
    Hadji, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 117 - 118
  • [2] The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
    Hadji, Peyman
    Ziller, May
    Maurer, Tobias
    Autenrieth, Michael
    Muth, Mathias
    Ruebel, Amelie
    May, Christoph
    Birkholz, Katrin
    Diebel, Erhardt
    Gleissner, Jochen
    Rothe, Peter
    Gschwend, Juergen E.
    JOURNAL OF BONE ONCOLOGY, 2012, 1 (03) : 88 - 94
  • [3] The Zotect study: Effect of zoledronic acid (Zometa®) on Bone Metabolism in Patients with Nreast or Prostate cancer with Bone metastases.
    Gschwendt, J.
    Ziller, M.
    Kalder, M.
    Lux, C.
    Maurer, T.
    Muth, M.
    Schmidt, K.
    Hadji, P.
    ONKOLOGIE, 2010, 33 : 204 - 204
  • [4] Safety of oral ibandronate and intravenous zoledronic acid in breast cancer patients with metastatic bone disease
    Body, JJ
    Lichinitser, MR
    Tjulandin, SA
    Coleman, RE
    Bergström, B
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S260 - S260
  • [5] Zoledronic acid palliation in bone-metastatic breast cancer
    Furlow, Bryant
    LANCET ONCOLOGY, 2006, 7 (11): : 894 - 894
  • [6] Safety of zoledronic acid in bone metastatic breast cancer patients:: A retrospective analysis
    Ferraro, Giuseppa
    Caristi, Nicola
    Sacca, Marcello Maugeri
    Arcana, Concetta
    Adamo, Barbara
    Briguglio, Roberta
    Zanghi, Mariangela
    Adamo, Vincenzo
    ANNALS OF ONCOLOGY, 2007, 18 : 46 - 46
  • [7] A time-in-motion study of oral ibandronic acid versus intravenous zoledronic acid for treatment of metastatic bone disease in breast cancer patients in the UK
    Wardley, A
    Body, JJ
    Neary, M
    Lewis, G
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S135 - S135
  • [8] Renal Safety of Intravenous Ibandronic Acid in Breast Cancer Patients with Metastatic Bone Disease
    Nina V. Lyubimova
    Nikolay E. Kushlinsky
    Michail R. Lichinitser
    Karl Schlosser
    Clinical Drug Investigation, 2003, 23 : 707 - 716
  • [9] Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease
    Lyubimova, NV
    Kushlinsky, NE
    Lichinitser, MR
    Schlosser, K
    CLINICAL DRUG INVESTIGATION, 2003, 23 (11) : 707 - 716
  • [10] Effect of intravenous zoledronic acid (ZA) on bone metastasis in patients with metastatic renal cell cancer (mRCC)
    Gruenwald, V.
    Wirth, M.
    Zantl, N.
    Schulze, M.
    May, C.
    Ruebel, A.
    Tunn, U.
    ONKOLOGIE, 2010, 33 : 88 - 88
12345